H. Lundbeck A / S Denmark

11.09.2025 - 08:32:08

Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® in patients severely impacted by migraine

Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb)New data from the open-label extension of the RESOLUTION trial and the primary results of the SUNSET extension trial will be presented for the first time at IHC1,2Patients treated with eptinezumab experienced sustained reductions in migraine symptom and burden, including long-term reduction in monthly migraine days (MMDs) and improvements in patient-reported outcomes1,2 and connect with us via LinkedIn.

References:

1. Jensen RH et al. Oral presentation at IHC 2025

2. Takeshima T et al. ePresentation at IHC 2025

3. Yu S et al. Oral presentation at IHC 2025

4. Lipton RB et al. Oral presentation at IHC 2025

5. Tepper SJ et al. ePresentation at IHC 2025

6. Yu S et al. ePresentation at IHC 2025

7. Jensen RH, et al. Front. Neurol. 2023; 14:1114654

8. Villalón CM. Pharmacol Ther. 2009;124(3):309-323

9. Steiner TJ, et al. J Headache Pain. 2018;19(1):17

10. Gustavsson A, et al. Eur Neuropsychopharmacol. 2011;21(10):718-79

11. Lipton RB, et al. J Neurol. 2023; 270, 5692–5710